Suppr超能文献

新型阴阳离子表面活性剂囊泡疫苗可抵御土拉弗朗西斯菌LVS,并对土拉弗朗西斯菌Schu S4菌株提供显著的部分保护。

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

作者信息

Richard Katharina, Mann Barbara J, Stocker Lenea, Barry Eileen M, Qin Aiping, Cole Leah E, Hurley Matthew T, Ernst Robert K, Michalek Suzanne M, Stein Daniel C, Deshong Philip, Vogel Stefanie N

机构信息

Department of Microbiology and Immunology, School of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA.

出版信息

Clin Vaccine Immunol. 2014 Feb;21(2):212-26. doi: 10.1128/CVI.00738-13. Epub 2013 Dec 18.

Abstract

Francisella tularensis is a Gram-negative immune-evasive coccobacillus that causes tularemia in humans and animals. A safe and efficacious vaccine that is protective against multiple F. tularensis strains has yet to be developed. In this study, we tested a novel vaccine approach using artificial pathogens, synthetic nanoparticles made from catanionic surfactant vesicles that are functionalized by the incorporation of either F. tularensis type B live vaccine strain (F. tularensis LVS [LVS-V]) or F. tularensis type A Schu S4 strain (F. tularensis Schu S4 [Schu S4-V]) components. The immunization of C57BL/6 mice with "bare" vesicles, which did not express F. tularensis components, partially protected against F. tularensis LVS, presumably through activation of the innate immune response, and yet it failed to protect against the F. tularensis Schu S4 strain. In contrast, immunization with LVS-V fully protected mice against intraperitoneal (i.p.) F. tularensis LVS challenge, while immunization of mice with either LVS-V or Schu S4-V partially protected C57BL/6 mice against an intranasal (i.n.) F. tularensis Schu S4 challenge and significantly increased the mean time to death for nonsurvivors, particularly following the i.n. and heterologous (i.e., i.p./i.n.) routes of immunization. LVS-V immunization, but not immunization with empty vesicles, elicited high levels of IgG against nonlipopolysaccharide (non-LPS) epitopes that were increased after F. tularensis LVS challenge and significantly increased early cytokine production. Antisera from LVS-V-immunized mice conferred passive protection against challenge with F. tularensis LVS. Together, these data indicate that functionalized catanionic surfactant vesicles represent an important and novel tool for the development of a safe and effective F. tularensis subunit vaccine and may be applicable for use with other pathogens.

摘要

土拉弗朗西斯菌是一种革兰氏阴性、具有免疫逃避能力的球杆菌,可导致人类和动物患兔热病。目前尚未研发出一种安全有效的、能抵御多种土拉弗朗西斯菌菌株的疫苗。在本研究中,我们测试了一种使用人工病原体的新型疫苗方法,即由阴阳离子表面活性剂囊泡制成的合成纳米颗粒,这些囊泡通过掺入土拉弗朗西斯菌B型活疫苗株(土拉弗朗西斯菌LVS [LVS-V])或土拉弗朗西斯菌A型舒S4株(土拉弗朗西斯菌舒S4 [舒S4-V])成分进行功能化修饰。用不表达土拉弗朗西斯菌成分的“空白”囊泡免疫C57BL/6小鼠,可部分抵御土拉弗朗西斯菌LVS,推测是通过激活先天免疫反应实现的,但它无法抵御土拉弗朗西斯菌舒S4株。相比之下,用LVS-V免疫可使小鼠完全抵御腹腔内(i.p.)土拉弗朗西斯菌LVS攻击,而用LVS-V或舒S4-V免疫小鼠可部分保护C57BL/6小鼠抵御鼻内(i.n.)土拉弗朗西斯菌舒S4攻击,并显著延长非存活小鼠的平均死亡时间,尤其是在鼻内和异源(即腹腔内/鼻内)免疫途径之后。LVS-V免疫而非空白囊泡免疫可诱导产生高水平的针对非脂多糖(non-LPS)表位的IgG,这些IgG在土拉弗朗西斯菌LVS攻击后增加,并显著增加早期细胞因子的产生。来自LVS-V免疫小鼠的抗血清可对土拉弗朗西斯菌LVS攻击提供被动保护。总之,这些数据表明功能化的阴阳离子表面活性剂囊泡是开发安全有效的土拉弗朗西斯菌亚单位疫苗的重要且新颖的工具,可能也适用于其他病原体。

相似文献

6
Characterization of Schu S4 mutants as live attenuated tularemia vaccine candidates.
Virulence. 2020 Dec;11(1):283-294. doi: 10.1080/21505594.2020.1746557.
9
Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent subsp. .
Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018.

引用本文的文献

1
The immune response to .
Front Microbiol. 2025 Apr 25;16:1549343. doi: 10.3389/fmicb.2025.1549343. eCollection 2025.
2
Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets against : an approach.
Front Immunol. 2025 Apr 3;16:1479862. doi: 10.3389/fimmu.2025.1479862. eCollection 2025.
3
Avirulence of a spontaneous Francisella tularensis subsp. mediasiatica prmA mutant.
PLoS One. 2024 Jun 18;19(6):e0305569. doi: 10.1371/journal.pone.0305569. eCollection 2024.
4
Development, Strategies, and Challenges for Tularemia Vaccine.
Curr Microbiol. 2024 Apr 2;81(5):126. doi: 10.1007/s00284-024-03658-0.
5
Evaluating methods to create protein functionalized catanionic vesicles.
Soft Matter. 2023 Feb 15;19(7):1429-1439. doi: 10.1039/d2sm01205g.
6
Catanionic Vesicles as a Facile Scaffold to Display Natural N-Glycan Ligands for Probing Multivalent Carbohydrate-Lectin Interactions.
Bioconjug Chem. 2023 Feb 15;34(2):392-404. doi: 10.1021/acs.bioconjchem.2c00560. Epub 2023 Jan 15.
8
Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.
Biomolecules. 2021 Jun 15;11(6):892. doi: 10.3390/biom11060892.
9
Dissociation of TRIF bias and adjuvanticity.
Vaccine. 2020 Jun 2;38(27):4298-4308. doi: 10.1016/j.vaccine.2020.04.042. Epub 2020 May 7.
10
Catanionic Surfactant Vesicles as a New Platform for probing Glycan-Protein Interactions.
Adv Funct Mater. 2018 Mar 28;28(13). doi: 10.1002/adfm.201706215. Epub 2018 Jan 19.

本文引用的文献

1
Caspase-1 activity affects AIM2 speck formation/stability through a negative feedback loop.
Front Cell Infect Microbiol. 2013 Apr 24;3:14. doi: 10.3389/fcimb.2013.00014. eCollection 2013.
2
Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.
4
Mechanisms of Francisella tularensis intracellular pathogenesis.
Cold Spring Harb Perspect Med. 2013 Apr 1;3(4):a010314. doi: 10.1101/cshperspect.a010314.
5
Vaccine delivery using nanoparticles.
Front Cell Infect Microbiol. 2013 Mar 25;3:13. doi: 10.3389/fcimb.2013.00013. eCollection 2013.
6
Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.
Infect Immun. 2013 Jun;81(6):2028-42. doi: 10.1128/IAI.00207-13. Epub 2013 Mar 25.
7
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.
Infect Immun. 2013 Feb;81(2):585-97. doi: 10.1128/IAI.01249-12. Epub 2012 Dec 10.
8
A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.
PLoS One. 2012;7(11):e50460. doi: 10.1371/journal.pone.0050460. Epub 2012 Nov 28.
10
Caspase-1: is IL-1 just the tip of the ICEberg?
Cell Death Dis. 2012 Jul 5;3(7):e338. doi: 10.1038/cddis.2012.86.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验